Literature DB >> 9273991

Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases.

S Kanzler1, G Gerken, H P Dienes, K H Meyer zum Büschenfelde, A W Lohse.   

Abstract

Autoimmune hepatitis is a chronic inflammatory disorder of the liver with a fluctuating course, which often requires long-term immunosuppressive therapy in order to prevent fibrosis to the liver. The mainstay of immunosuppressive therapy is the use of corticosteroids, usually in conjunction with azathioprine. However, in a subgroup of patients with severe side effects or intolerance of standard therapy there is a need for alternative immunosuppressive agents. We describe the successful long-term treatment of three patients with severe autoimmune hepatitis with an immunosuppressive regimen consisting of cyclophosphamide and corticosteroids. In the reported patients we were able to induce remission with cyclophosphamide in a dose of 1-1.5 mg/kg bodyweight in combination with a tapering dose of corticosteroids beginning with 1 mg/kg bodyweight. After induction we were able to maintain histology proven remission with low doses of corticosteroids (2.5-10 mg/day) together with 50 mg of cyclophosphamide every other day. With this dose of cyclophosphamide we have neither observed relapse of autoimmune hepatitis nor severe side effects in a cumulative observation period of more than twelve years in the three patients. As a consequence of our favourable experience with cyclophosphamide in the reported cases, we propose cyclophosphamide as an alternative to azathioprine in cases of autoimmune hepatitis with severe side effects of intolerance of standard therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9273991

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  16 in total

1.  Multiplex neuritis in a patient with autoimmune hepatitis: a case report.

Authors:  S Luth; F Birklein; C Schramm; J Herkel; E Hennes; W Muller-Forell; P R Galle; A W Lohse
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

2.  Autoimmune hepatitis.

Authors:  Joseph Ahn; Steven L Flamm
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

3.  Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.

Authors:  Kelly W Burak; Mark G Swain; Tania Santodomingo-Garzon; Tania Santodomino-Garzon; Samuel S Lee; Stefan J Urbanski; Alexander I Aspinall; Carla S Coffin; Robert P Myers
Journal:  Can J Gastroenterol       Date:  2013       Impact factor: 3.522

4.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 5.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

6.  Treatment of Autoimmune Hepatitis: Current and Future Therapies.

Authors:  Fernando Alvarez
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

Review 7.  Update on autoimmune hepatitis.

Authors:  Andreas Teufel; Peter R Galle; Stephan Kanzler
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

Review 8.  Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  The use of budesonide in the treatment of autoimmune hepatitis in Canada.

Authors:  Iman Zandieh; Darin Krygier; Victor Wong; John Howard; Lawrence Worobetz; Gerald Minuk; Helga Witt-Sullivan; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

10.  Treatment of autoimmune liver disease: current and future therapeutic options.

Authors:  Palak J Trivedi; Gideon M Hirschfield
Journal:  Ther Adv Chronic Dis       Date:  2013-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.